The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1630
August 9, 2021
View Complete Issue         Table of Contents 2019 
Fenfluramine (Fintepla) for Dravet Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fenfluramine (Fintepla) for Dravet Syndrome
August 9, 2021 (Issue: 1630)
The FDA has approved fenfluramine oral solution (Fintepla – Zogenix) for treatment of seizures in patients ≥2 years old with Dravet syndrome. It is the third drug to be approved for this indication. Stiripentol (Diacomit) and cannabidiol...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fenfluramine (Fintepla) for Dravet Syndrome
Article code: 1630d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.